Dialysis News and Research

Latest Dialysis News and Research

Better medical care for kidney failure in Germany

In complex cases of kidney failure, medical care in Germany evidently operates better than in the US. Scientists at Charité - Universitätsmedizin Berlin were able to show that German patients who have an increased risk of rejection reactions due to prior immunization have better survival rates than people with diseases of similar severity in the US.

3 Dec 2011

Potential test to diagnose membranous nephropathy in early stages

Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose membranous nephropathy in its early stages.

1 Dec 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

Acetaminophen over-use can lead to serious liver damage

Common pain and fever Acetaminophen (best known by the brand name Tylenol) taken over a long time can cause liver failure and death, according to a new study.

24 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Diaverum signs joint venture agreement with Nazer Group

November 2011: Diaverum, one of the world´s largest independent renal care providers, has signed a joint venture agreement with Nazer Group, a Saudi Arabian Holding Company with major investments in the medical sector including Bupa Arabia.

22 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

AMAG Pharmaceuticals, Inc. today announced positive new data from the FIRST head-to-head trial comparing Feraheme (ferumoxytol) Injection for intravenous (IV) use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease.

14 Nov 2011

Maintaining normal blood glucose levels prevents long-term kidney complications

Maintaining good glucose control early in the course of type 1 diabetes could lessen the long-term risk of kidney disease, as measured by a common test of kidney function.

14 Nov 2011

New information on kidney-related policies in the U.S.

Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on kidney-related policies in the United States.

14 Nov 2011

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease.

14 Nov 2011

Updates on dietary benefits and dangers in kidney disease patients

Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on dietary benefits and dangers in kidney disease patients.

11 Nov 2011

Diabetics with kidney failure should not lower their hemoglobin A1C levels

Two separate studies presented during the American Society of Nephrology's Annual Kidney Week agree that diabetics with kidney failure shouldn't lower their blood glucose levels as much as diabetics without kidney failure.

11 Nov 2011

Pediatric racial minorities less likely to get kidney transplants

Among children with kidney disease, certain races are less likely to get kidney transplants and are more likely to die than other races, according to two studies from Emory University that were presented during the American Society of Nephrology's Annual Kidney Week.

11 Nov 2011

Fresenius Medical Care receives FDA clearance for 2008T hemodialysis delivery system

At the American Society of Nephrology's Kidney Week 2011, Fresenius Medical Care, the world's largest provider of dialysis products and services, announced that it received U.S. Food and Drug Administration 510 (K) clearance to extend improved touch screen navigation on its most advanced hemodialysis delivery system, the 2008T.

9 Nov 2011

American Access Care sold to to Fresenius Medical Care

TA Associates, a leading global growth private equity firm, today announced the sale of its portfolio company American Access Care (AAC) to Fresenius Medical Care AG & Co. KGaA.

7 Nov 2011

MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. announced that it has executed the formal closing documents and acquired the chronic kidney disease formula. This formula was developed to restore proper kidney function.

7 Nov 2011

Patients with lupus nephritis ESRD choose hemodialysis as initial therapy

Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation.

7 Nov 2011

AHRQ awarded $34M in fiscal year 2011 to expand fight against HAIs

The U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality announced that it has awarded $34 million in fiscal year 2011 for grants and contracts to hospitals, academic medical institutions, and health care research organizations to expand the fight against healthcare-associated infections.

5 Nov 2011